Learn More
BACKGROUND HIV-infected patients receiving antiretroviral therapy often demonstrate excess visceral fat. A growth hormone-releasing factor, tesamorelin, may selectively reduce visceral fat in this population. We investigated the effects of tesamorelin (GHRH(1-44)) in HIV-infected patients with central fat accumulation. METHODS A 12-month study of 404(More)
BACKGROUND Tesamorelin, a growth hormone-releasing hormone analogue, decreases visceral adipose tissue (VAT) by 15%-20% over 6-12 months in individuals with human immunodeficiency virus (HIV)-associated abdominal adiposity, but it is unknown whether VAT reduction is directly associated with endocrine and metabolic changes. METHODS In 2 phase III,(More)
This article introduces a state-space model for the dynamic modeling of curve sequences within the framework of railway switches online monitoring. In this context, each curve has the peculiarity of being subject to multiple changes in regime. The proposed model consists of a specific latent variable regression model whose coefficients are supposed to(More)
  • 1